Volume 3, Issue 2, p29-65
Articles published in this issue are Open Access and licensed under Creative Commons Attribution License (CC BY NC) where the readers can reuse, download, distribute the article in whole or part by mentioning proper credits to the authors.
COVID-19, a global pandemic caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV2) has resulted in hospitalization in many cases.Arch Pharmacol Ther, 2021, Volume 3, Issue 2, p29-31 | DOI: 10.33696/Pharmacol.3.024
Diabetes mellitus is one of the most common chronic diseases that affect people of all ages and races worldwide.Arch Pharmacol Ther, 2021, Volume 3, Issue 2, p32-36 | DOI: 10.33696/Pharmacol.3.025
Study of the Tableting Properties of MCR, a Newly Coprocessed Cellulose-based Direct Compression Excipient
The current need for strategies to accelerate and optimize the efforts to develop new in-expensive multifunctional direct compression tableting excipients with minimum risk to the products has urged the workers in pharmaceutical industry field to search for a simple and low cost-effective technique to tailor and engineer multi-functional excipients.Arch Pharmacol Ther, 2021, Volume 3, Issue 2, p37-38 | DOI: 10.33696/Pharmacol.3.026
Nematocidal Effect of Japanese Traditional Intestinal Medicine ‘Seirogan’ on Larval Anisakid and Raphidascaridid Nematodes
‘Seirogan’ is a well-known Japanese traditional herbal medicine for stomachache or diarrhea due to digestive disorders.Arch Pharmacol Ther, 2021, Volume 3, Issue 2, p48-51 | DOI: 10.33696/Pharmacol.3.027
Inhaled budesonide benefits patients with COVID-19. ProLung™-budesonide enables the sustained, low dose administration of budesonide within a delivery vehicle similar to lung surfactant.Arch Pharmacol Ther, 2021, Volume 3, Issue 2, p52-65 | DOI: 10.33696/Pharmacol.3.028
Scientific Archives is a global publisher initiated with the mission of ensuring equal opportunity for accessing science to research community all over the world. Spreading research findings with great relevance to all channels without any barrier is our goal. We want to overcome the challenges of Open Access with ensured quality and transparency.